Compare Summit Therapeutics Inc (SMMT) vs Advanced Drainage Systems Inc (WMS) Price & Performance

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.

WMS trades at $140.22, down 1.02% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings of $2.49 per share, beating estimates, and maintains solid profitability with a 14% net income margin. Recent news highlights Q1 2027 revenue growth of 21% year-over-year and a quarterly dividend declaration.

The outlook is mixed: analyst consensus is a Buy with a $185.86 price target, implying upside, but technical weakness and a Zacks Strong Sell rating (June 22, 2026) pose near-term risks. Investment appeal hinges on execution of growth initiatives amid competitive pressures and debt levels.